Publication Name	World Journal of Hematology
Manuscript ID	10025
Country	Japan

Received	2014-03-09 17:10
Peer-Review Started	2014-03-10 08:45
To Make the First Decision	2014-04-28 14:34
Return for Revision	2014-04-30 15:00
Revised	2014-05-09 16:37
Second Decision	2014-06-18 14:58
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-18 15:17
Articles in Press	2014-06-18 15:42
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-06-24 03:01
Typeset the Manuscript	2014-09-28 17:48
Publish the Manuscript Online	2014-10-20 10:04

ISSN	2218-6204 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment
Manuscript Source	Invited Manuscript
All Author List	Shinsaku Imashuku
Funding Agency and Grant Number
Corresponding Author	Shinsaku Imashuku, MD, PhD Consultant to the Department of Laboratory Medicine, Uji-Tokushukai Medical Center 86 Kasugamori, Ogura-cho, Uji, Kyoto, Japan 611-0042 Tel: +81-774-20-1111; FAX +81-0774-20-2336 E-mail: shinim95@mbox.kyoto-inet.or.jp
Key Words	hemophagocytic lymphohistiocytosis; ; molecular diagnosis; hematopoietic stem-cell transplantation; cyclosporine A; rituximab
Core Tip	This review discusses the diagnostic criteria for HLH, the algorithms used to identify the underlying immune defects at the molecular level, and the optimal therapeutic approaches. For any HLH cases, a screening for primary HLH should be made following the diagnostic algorithm. During the process, immunosuppressive therapy should be started to control the hypercytokinemia with steroids, CSA, or IVIG, and if primary HLH is confirmed, immunochemotherapy with a regimen containing etoposide or ATG should be given. Supportive measures to control hemorrhage/organ dysfunction are also required. In cases of primary HLH or secondary/refractory HLH, timely allogeneic hematopoietic stem-cell transplantation is recommended.
Publish Date	2014-10-20 10:04
Citation	Imashuku S. Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment. World J Hematol 2014; 3(3): 71-84
URL	http://www.wjgnet.com/2218-6204/full/v3/i3/71.htm
DOI	http://dx.doi.org/10.5315/wjh.v3.i3.71

Full Article (PDF)	WJH-3-71.pdf
Full Article (Word)	WJH-3-71.doc
Manuscript File	10025-Review.docx
Answering Reviewers	10025-Answering reviewers.pdf
Copyright License Agreement	10025-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20140309092311.pdf
Peer-review Report	10025-Peer review(s).pdf
Scientific Misconduct Check	10025-CrossCheck.jpg
Scientific Editor Work List	10025-Scientific editor work list.pdf